Saturday December 16th 2017

Auxogyn signs exclusive license agreement with Merck Serono for Eeva Test

Auxogyn, Inc., a company dedicated to advancing women’s reproductive health, today announced an exclusive license agreement with Merck Serono, the biopharmaceutical division of Merck KGaA, Darmstadt, Germany which operates as EMD Serono in the United States and Canada, for Auxogyn’s proprietary Early Embryo Viability Assessment (Eeva) Test.

See original¬†–¬†

Auxogyn signs exclusive license agreement with Merck Serono for Eeva Test

Leave a Comment

More from category

MS Activists Celebrate 2017 State Policy Impact
MS Activists Celebrate 2017 State Policy Impact

/About-the-Society/News/MS-Activists-Celebrate-2017-State-Policy-Impact [Read More]

MS Research Program Funding Authorized by President Trump
MS Research Program Funding Authorized by President Trump

/About-the-Society/News/MS-Research-Program-Funding-Authorized-by-Presiden [Read More]

Germany’s Merck to make new bid to enter U.S. MS pill market
Germany’s Merck to make new bid to enter U.S. MS pill market

FRANKFURT (Reuters) - Germany's Merck KGaA is reviving plans to bring an oral multiple sclerosis (MS) treatment to the [Read More]

Researchers develop new method for quickly detecting signs of multiple sclerosis
Researchers develop new method for quickly detecting signs of multiple sclerosis

A METHOD for quickly detecting signs of multiple sclerosis has been developed by a University of Huddersfield research [Read More]

Terror survivors have increased risk of frequent migraine, tension headaches
Terror survivors have increased risk of frequent migraine, tension headaches

Survivors of a terror attack have an increased risk of frequent migraine and tension headaches after the attack, [Read More]